<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794466</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00143045</org_study_id>
    <nct_id>NCT03794466</nct_id>
  </id_info>
  <brief_title>Quantify the Degree of Pain Relief of Pelvic Congestion Syndrome Following Gonadal Vein Embolization</brief_title>
  <official_title>Quantification of Pain Relief With Gonadal Vein Embolization for Pelvic Congestion Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to quantify the degree of pain relief in patients undergoing gonadal
      vein embolization with coils as well as identify clinical or imaging factors that are
      predictive of a positive response to treatment, or poor response to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pelvic pain affects almost 40% of women during their lifetime. Pelvic congestion
      syndrome (PCS) accounts for up to 30% of those with chronic pelvic pain. The most common
      underlying cause of PCS is incompetence or obstruction of the gonadal veins, resulting in
      painful congestion of the pelvic and perineal venous vasculature. Medical treatment is first
      line, and aims to suppress ovarian function and induce vasoconstriction of the venous system.
      Unfortunately, efficacy and long-term pain relief from medical therapy is limited. Coil
      embolization of the gonadal veins has been shown to decrease pain in those affected by PCS,
      although the degree of relief has not yet been quantified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">September 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify pain relief using the Pelvic Congestion Symptom Pain Scale after gonadal vein embolization</measure>
    <time_frame>Change from baseline (before gonadal vein embolization) to 360 days post-procedure.</time_frame>
    <description>quantify the degree of pain relief in patients undergoing gonadal vein embolization with coils using a survey consisting 4 questions. Answers will be given values 0-4, which higher values are considered to be worse outcomes. One question is &quot;On average, how many days a week do you experience pelvic pain?&quot; Answers would be none (0), 1-2 days a week (1), 3-4 days a week (2), 5-6 days a week (3), and every day of the week (4). Maximum total amount of points will be 16. This is the number of points added together from all 4 questions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predict positive or poor response to gonadal vein embolization treatment</measure>
    <time_frame>Change from baseline (before gonadal vein embolization) to 360 days post-procedure.</time_frame>
    <description>Identify clinical or imaging factors that are predictive of a positive response to treatment, or poor response to treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pelvic Congestive Syndrome</condition>
  <condition>Pelvic Pain</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women, 18 years of age and older, who are candidates for gonadal vein embolization in the
        Interventional Radiology division at the University of Kansas Medical Center from October
        1, 2018 to October 1, 2019.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients 18 years of age or older

          -  Meet the clinical and imaging criteria for the diagnosis of PCS and have no
             contraindications to coil embolization of the gonadal veins.

          -  Patients who are treated with coil embolization of the gonadal veins in the
             Interventional Radiology division between October 1, 2018 to October 1, 2019.

        Exclusion Criteria:

          -  Patients less than 18 years of age.

          -  Patients who are found to have an underlying cause of pelvic congestion syndrome
             unrelated to venous congestion and insufficiency. This includes, but is not limited
             to, nutcracker syndrome, or a mass resulting in extrinsic compression of the gonadal
             veins.

          -  Patients who have received prior surgical therapy for PCS, including bilateral
             salpingo-oophorectomy (TAH-BSO), gonadal vein resection, or gonadal vein ligation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam S Alli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carissa Walter, MPH</last_name>
    <phone>9139457450</phone>
    <email>cwalter2@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Walter, MPH</last_name>
      <phone>913-945-7450</phone>
      <email>cwalter2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam S Alli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Kirkpatrick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Lemons, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Custer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Johnson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zachary Collins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ignacio EA, Dua R, Sarin S, Harper AS, Yim D, Mathur V, Venbrux AC. Pelvic congestion syndrome: diagnosis and treatment. Semin Intervent Radiol. 2008 Dec;25(4):361-8. doi: 10.1055/s-0028-1102998.</citation>
    <PMID>21326577</PMID>
  </reference>
  <reference>
    <citation>O'Brien MT, Gillespie DL. Diagnosis and treatment of the pelvic congestion syndrome. J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):96-106. doi: 10.1016/j.jvsv.2014.05.007. Epub 2014 Jun 25. Review.</citation>
    <PMID>26993690</PMID>
  </reference>
  <reference>
    <citation>Koo S, Fan CM. Pelvic congestion syndrome and pelvic varicosities. Tech Vasc Interv Radiol. 2014 Jun;17(2):90-5. doi: 10.1053/j.tvir.2014.02.005. Review.</citation>
    <PMID>24840963</PMID>
  </reference>
  <reference>
    <citation>Lopez AJ. Female Pelvic Vein Embolization: Indications, Techniques, and Outcomes. Cardiovasc Intervent Radiol. 2015 Aug;38(4):806-20. doi: 10.1007/s00270-015-1074-7. Epub 2015 Mar 25. Review.</citation>
    <PMID>25804635</PMID>
  </reference>
  <reference>
    <citation>Daniels JP, Champaneria R, Shah L, Gupta JK, Birch J, Moss JG. Effectiveness of Embolization or Sclerotherapy of Pelvic Veins for Reducing Chronic Pelvic Pain: A Systematic Review. J Vasc Interv Radiol. 2016 Oct;27(10):1478-1486.e8. doi: 10.1016/j.jvir.2016.04.016. Epub 2016 Jul 7. Review.</citation>
    <PMID>27397619</PMID>
  </reference>
  <reference>
    <citation>Brown CL, Rizer M, Alexander R, Sharpe EE 3rd, Rochon PJ. Pelvic Congestion Syndrome: Systematic Review of Treatment Success. Semin Intervent Radiol. 2018 Mar;35(1):35-40. doi: 10.1055/s-0038-1636519. Epub 2018 Apr 5. Review.</citation>
    <PMID>29628614</PMID>
  </reference>
  <reference>
    <citation>Guirola JA, SÃ¡nchez-Ballestin M, Sierre S, Lahuerta C, Mayoral V, De Gregorio MA. A Randomized Trial of Endovascular Embolization Treatment in Pelvic Congestion Syndrome: Fibered Platinum Coils versus Vascular Plugs with 1-Year Clinical Outcomes. J Vasc Interv Radiol. 2018 Jan;29(1):45-53. doi: 10.1016/j.jvir.2017.09.011. Epub 2017 Nov 22.</citation>
    <PMID>29174618</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gonadal vein embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03794466/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

